JAK1 and pulmonary fibrosis: Our results show that JAK1/2 and STAT3 were activated in animal and cell models of pulmonary fibrosis and that baricitinib has therapeutic effects on pulmonary fibrosis by selectively inhibiting JAK1/2, including reducing the collagen deposition and improving pulmonary function in BLM-injured mice.